PRESS RELEASE published on 07/03/2024 at 08:12, 1 year 5 months ago CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities CureVac initiates strategic restructuring to focus on high-value mRNA pipeline opportunities, including workforce reduction and new GSK agreement Oncology Strategic Restructuring CureVac MRNA Pipeline GSK Agreement
PRESS RELEASE published on 07/03/2024 at 08:09, 1 year 5 months ago GSK and CureVac to Restructure Collaboration into New Licensing Agreement GSK and CureVac restructure collaboration into new licensing agreement for mRNA vaccines development, manufacturing, and commercialization globally Licensing Agreement Collaboration GSK MRNA Vaccines CureVac
BRIEF published on 06/24/2024 at 22:10, 1 year 5 months ago CureVac Announces Voting Results of General Meeting Annual General Meeting Voting Results Board Appointments CureVac MRNA
PRESS RELEASE published on 06/24/2024 at 22:05, 1 year 5 months ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of the general meeting, including board appointments and auditor reappointment. Shareholders voted in favor of all proposals Appointments Voting Results General Meeting CureVac Auditor Reappointment
BRIEF published on 05/28/2024 at 13:05, 1 year 6 months ago CureVac Announces Dosing of First Participant in Phase 2 Influenza Study GSK MRNA Technology Phase 2 Study CureVac Influenza Vaccine
PRESS RELEASE published on 05/28/2024 at 13:00, 1 year 6 months ago CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK CureVac initiates Phase 2 study in collaboration with GSK for seasonal influenza vaccine, targeting improved immune responses against influenza B strain GSK Vaccine Development Phase 2 Study CureVac Seasonal Influenza
BRIEF published on 05/23/2024 at 13:05, 1 year 6 months ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update Financial Results Business Update Q1 2024 CureVac FDA Fast Track
PRESS RELEASE published on 05/23/2024 at 13:00, 1 year 6 months ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update CureVac announces financial results for Q1 2024, reports €300.2 million cash position and updates on organizational restructuring and patent litigations Financial Results Cash Position CureVac Patent Litigation Organizational Redesign
BRIEF published on 04/24/2024 at 13:11, 1 year 7 months ago CureVac Announces 2023 Financial Results and Strategic Business Updates MRNA Technology CureVac Pharmaceutical Collaborations Oncology Vaccines Prophylactic Vaccines
BRIEF published on 04/24/2024 at 13:08, 1 year 7 months ago CureVac Begins Combined Phase 1/2 Study for Avian Influenza H5N1 Vaccine with GSK GSK CureVac Phase 1/2 Study Influenza H5N1 MRNA Vaccine
Published on 12/05/2025 at 02:35, 9 hours 13 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 10 hours 48 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 12 hours 43 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 12 hours 48 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 10:30, 1 hour 18 minutes ago Tradegate Exchange and Börse Berlin merge to form Tradegate BSX
Published on 12/05/2025 at 10:15, 1 hour 33 minutes ago Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 2 hours 8 minutes ago Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 2 hours 18 minutes ago REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 08:45, 3 hours 3 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 17 hours 48 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 18 hours 3 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 18 hours 4 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 4 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
